Alpha-Synuclein Imaging Probe With Selective Aggregate Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compounds, such as PBB3, have low binding selectivity for α-synuclein aggregates, making them unsuitable as effective probes for imaging and inhibiting these aggregates, which are central to diseases like Parkinson's disease and dementia with Lewy bodies.
Innovation Solution
Development of a compound represented by formula (I) with a buteninyl structure and benzothiazole or benzofuran structure, which exhibits high binding selectivity for α-synuclein aggregates, enabling optical and radiological imaging, and potential inhibition of α-synuclein aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PBB3 is used as an α-synuclein aggregate probe, then imaging capability is achieved, but binding selectivity is low
Solution Approach 1:
The patent modifies the chemical structure of PBB3 by introducing a fluorine atom at the 4-position of the pyridine ring to create FBPP. This parameter change (adding fluorine substitution) enhances the binding selectivity for α-synuclein aggregates while preserving the imaging capability, thereby resolving the contradiction between measurement precision and reliability
Solution Approach 2:
The patent creates a composite molecular structure combining the benzothiazole-butenyl-pyridine scaffold with a fluorine atom and hydroxy group substitutions. This composite structure achieves both high binding selectivity for α-synuclein aggregates and sufficient imaging capability, simultaneously satisfying both requirements that were in contradiction
2Adaptability or versatility
If a compound binds to both α-synuclein and tau aggregates, then broad disease coverage is achieved, but binding selectivity for α-synuclein is low
Solution Approach 1:
The patent introduces a fluorine atom at the specific 4-position of the pyridine ring, creating a localized structural feature that confers selective affinity for α-synuclein aggregates. This local modification maintains the compound's ability to bind to aggregate structures generally while adding specific selectivity for α-synuclein, resolving the contradiction between versatility and selectivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound provides high selectivity for α-synuclein aggregates, allowing accurate imaging and potential inhibition, facilitating early diagnosis and therapeutic assessment of related diseases.
Implementation Method 1
a compound represented by formula (I), having a buteninyl structure and a benzothiazole or benzofuran structure, has high binding selectivity for the α-synuclein aggregate
Data Source
AI summary
The present invention provides an α-synuclein aggregate binding agent that has high binding selectivity for an α-synuclein aggregate.The α-synuclein aggregate binding agent contains a compound represented by a formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof:in the formula (I), R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; the ring A is a benzene or pyridine ring; the ring B is represented by the following formula (i) or (ii):R4 and R5 are each independently selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl.